BG103252A - The use of benzopyranols for the treatment of neurological disorders - Google Patents

The use of benzopyranols for the treatment of neurological disorders

Info

Publication number
BG103252A
BG103252A BG103252A BG10325299A BG103252A BG 103252 A BG103252 A BG 103252A BG 103252 A BG103252 A BG 103252A BG 10325299 A BG10325299 A BG 10325299A BG 103252 A BG103252 A BG 103252A
Authority
BG
Bulgaria
Prior art keywords
treatment
pains
benzopyranols
neurological disorders
neuralgia
Prior art date
Application number
BG103252A
Other languages
Bulgarian (bg)
English (en)
Inventor
Andrew Parsons
Mervyn Thompson
Neil Upton
Johan EVANS
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG103252A publication Critical patent/BG103252A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG103252A 1996-09-18 1999-03-15 The use of benzopyranols for the treatment of neurological disorders BG103252A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619492.3A GB9619492D0 (en) 1996-09-18 1996-09-18 Novel treatment
PCT/EP1997/005168 WO1998011890A1 (en) 1996-09-18 1997-09-15 Use of benzopyranols to treat neurological disorders

Publications (1)

Publication Number Publication Date
BG103252A true BG103252A (en) 1999-09-30

Family

ID=10800127

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103252A BG103252A (en) 1996-09-18 1999-03-15 The use of benzopyranols for the treatment of neurological disorders

Country Status (30)

Country Link
EP (1) EP0939630B1 (tr)
JP (1) JP2001500520A (tr)
KR (1) KR20000036184A (tr)
CN (1) CN1230885A (tr)
AP (1) AP9901473A0 (tr)
AR (1) AR008838A1 (tr)
AT (1) ATE270102T1 (tr)
AU (1) AU730465B2 (tr)
BG (1) BG103252A (tr)
BR (1) BR9712030A (tr)
CA (1) CA2266681A1 (tr)
DE (1) DE69729735T2 (tr)
DZ (1) DZ2311A1 (tr)
EA (1) EA199900306A1 (tr)
ES (1) ES2223075T3 (tr)
GB (1) GB9619492D0 (tr)
HU (1) HUP9904638A3 (tr)
ID (2) ID23175A (tr)
IL (1) IL128786A0 (tr)
MA (1) MA24321A1 (tr)
NO (1) NO991292L (tr)
NZ (1) NZ334271A (tr)
OA (1) OA10998A (tr)
PE (1) PE109898A1 (tr)
PL (1) PL332313A1 (tr)
SK (1) SK35199A3 (tr)
TR (1) TR199900527T2 (tr)
UY (1) UY24717A1 (tr)
WO (1) WO1998011890A1 (tr)
ZA (1) ZA978359B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US20130281524A1 (en) * 2008-06-05 2013-10-24 Peter Blower Novel treatments
CA2726874A1 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
EA025824B1 (ru) 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
RU2012124838A (ru) * 2009-12-03 2014-01-10 Проксимэджен ЛТД Лечение инфекционных заболеваний
CA2782625A1 (en) * 2009-12-03 2011-06-09 Proximagen Ltd Treatment of allodynia and hyperalgesia
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (tr) 2011-07-01 2018-04-28
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112721D0 (en) * 1991-06-13 1991-07-31 Smithkline Beecham Plc Novel treatment
US5510375A (en) * 1993-11-19 1996-04-23 Warner-Lambert Company Coumarin derivatives as protease inhibitors and antiviral agents
CN1234702C (zh) * 1994-06-10 2006-01-04 史密丝克莱恩比彻姆有限公司 苯并吡喃类化合物和包含它们的药物组合物
GB9411635D0 (en) * 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
ATE270102T1 (de) 2004-07-15
JP2001500520A (ja) 2001-01-16
DE69729735D1 (de) 2004-08-05
NO991292D0 (no) 1999-03-17
KR20000036184A (ko) 2000-06-26
NO991292L (no) 1999-03-17
ID23175A (id) 2000-03-23
MA24321A1 (fr) 1998-04-01
DE69729735T2 (de) 2005-07-14
AU4704797A (en) 1998-04-14
AR008838A1 (es) 2000-02-23
ID19542A (id) 1998-07-23
ZA978359B (en) 1999-03-17
PE109898A1 (es) 1999-03-21
CA2266681A1 (en) 1998-03-26
UY24717A1 (es) 2001-08-27
TR199900527T2 (tr) 1999-06-21
EP0939630B1 (en) 2004-06-30
AP9901473A0 (en) 1999-03-31
BR9712030A (pt) 1999-08-24
EP0939630A1 (en) 1999-09-08
HUP9904638A3 (en) 2001-08-28
IL128786A0 (en) 2000-01-31
NZ334271A (en) 2001-03-30
WO1998011890A1 (en) 1998-03-26
CN1230885A (zh) 1999-10-06
OA10998A (en) 2003-03-04
DZ2311A1 (fr) 2002-12-28
AU730465B2 (en) 2001-03-08
PL332313A1 (en) 1999-08-30
ES2223075T3 (es) 2005-02-16
EA199900306A1 (ru) 1999-08-26
GB9619492D0 (en) 1996-10-30
HUP9904638A2 (hu) 2001-05-28
SK35199A3 (en) 2000-07-11

Similar Documents

Publication Publication Date Title
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
EP0792156A4 (en) METHOD FOR PREVENTING OR TREATING VASCULAR HEMORRAGIES AND ALZHEIMERIC DISEASE
EP0467164A3 (en) Use of the compound flupirtine against muscle bracing
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
GB0108592D0 (en) Therapeutic agents
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
FR2706767B1 (tr)
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
BG103252A (en) The use of benzopyranols for the treatment of neurological disorders
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AP1749A (en) Method of treating of demyelinating diseases or conditions.
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
WO2000021513A3 (en) Methods for treating multiple sclerosis
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
BG102079A (en) Alkylaminoderivatives of substituted quinoxalin-2,3-dions such as glutamatereceptor antagonists
WO2003020221A3 (en) Method of treating cancerous disease
ZA985668B (en) (S)-2-methylamino-2-phenyl-n-butyl 3,4,5-trimethoxy benzoate its application to the treatment of chronic pain
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease